Protalix BioTherapeutics (PLX) Current Leases (2019 - 2026)

Protalix BioTherapeutics has reported Current Leases for 8 years, with the latest figure at $1.7 million in Q2 2026.

• On a quarterly basis, Current Leases rose 13.18% year-over-year to $1.7 million in Q2 2026; TTM through Jun 2026 was $1.7 million, a 13.18% increase from a year earlier, with the FY2025 full-year figure at $1.4 million, down 7.73% from the prior year.
• Current Leases was $1.7 million for Q2 2026 at Protalix BioTherapeutics, up from $1.4 million in the prior quarter.
• The five-year high for Current Leases was $1.7 million in Q2 2026, with the low at $1.0 million in Q3 2022.
• Average Current Leases over 5 years is $1.3 million, with a median of $1.4 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Current Leases declined 19.03% in 2022, then jumped 31.3% in 2023.
• Over 5 years, Current Leases stood at $1.1 million in 2022, then advanced by 26.03% to $1.4 million in 2023, then increased by 6.46% to $1.5 million in 2024, then fell by 7.73% to $1.4 million in 2025, then gained by 20.38% to $1.7 million in 2026.
• The last three Current Leases figures came in at $1.7 million (Q2 2026), $1.4 million (Q1 2026), and $1.4 million (Q4 2025), per Business Quant data.